STD-HIV/AIDS Market Analysis and Reports | UK Conference Series

Market Analysis - STD-HIV/AIDS 2017

Market Analysis Report:

According to the World Health Organization (WHO, 2015a), 498 million people ages 15 to 49 are infected every year with chlamydia, gonorrhea, syphilis, or trichomoniasis. It has also been estimated that 106 million people worldwide are infected specifically with gonorrhea each year. Gonorrhea infections can be cured by antibiotics, but untreated infections can lead to pelvic inflammatory disease (PID), ectopic pregnancies, premature deliveries, and infertility, all of which are more common in the developing world. Study results show that gonorrhea’s ability to develop resistance to treatment, such as extended-range cephalosporins, raises concern that the infection could become untreatable (Blomquist et al., 2014).

The rate of acquisition of viral STDs is increasing, and most viral infections cannot be cured by medicines. Data from the World Health Organization (WHO, 2015b) estimate a global figure of approximately 35 million people who are living with the human immunodeficiency virus (HIV). The same data show approximately 1,370,000 deaths by acquired immune deficiency syndrome (AIDS) worldwide in the countries reporting data (notably, the United States and China are not included in the reported data) (WHO, 2015b). But the disease progression in HIV/AIDS can be slowed by antiretroviral drugs (Bichoupan & Dieterich, 2014), and the frequency of outbreaks can be decreased by antiviral drugs, as in the case of herpes simplex virus (HSV).

Some STDs last a long time, and some STDs are incurable; therefore, the prevalence of STDs is much higher than their incidence. With over 19.7 million newly occurring STDs annually in the United States, rates of new STD infections are among the highest in the developed world. This is compared to 498 million newly occurring, curable STDs every year (Blomquist et al., 2014).

The cost is $15.6 billion/year for the eight most common newly diagnosed STDs in the United States. Part of this cost includes infection prevention efforts that address abstention, reducing the number of sexual partners, using condoms, and effective vaccines. Testing and prompt treatment are also part of the cost and can reduce expenses by preventing long-term effects. The greatest cost involves life-long treatment for certain STDs such as HIV and HPV-related cancers (CDC, 2013a).

Major Sexually Transmitted Diseases Associations Around the Globe:

European Society of Clinical Microbiology and Infectious Diseases

International Union of Microbiological Societies

Society for general Microbiology

Federation of Infection Societies

Canadian Society of Microbiologists

British Infection Association

Federation of European Microbiological Societies

Welsh Microbiology Association

Clinical Virology Network

Infectious Diseases Society of America

American Society for Microbiology

Top Universities Associated With STD’s:

Figure 1: Top Universities Associated With STD’s
Source: Reference: 8

Top Universities in Europe:

Figure 2:  Top Universities in Europe

Target Audience:

Industry       63%

Academia     30%

Others           7%

Figure3: Target Audience

Source: Reference 3

Companies Associated with STD’s

Figure 4:  Companies Associated with STD's

Source: Reference 4

Statistical Analysis of Associations:

Figure 5:  Statistical Analysis of Associations
Source: Reference 6

Percentage of Revenue Contribution for Research on STD’S:

Figure 6:  Percentage of Revenue Contribution for Research on STD’S

Top global pharmaceutical companies manufacturing antimicrobial products:

1)      Pfizer

2)      Merck and Co

3)      Johnson and Johnson

4)      GlaxoSmithKline

5)      Bristol-Meyers Squibb

6)      Aventis

7)      Pharmacia

8)      Novartis

9)      F. Hoffmann-La Roche

10)    Astra Zeneca

11)    Abott Laboratories

12)    Wyeth

13)    Eli Lilly and Co

14)    Schering Plough

15)     Bayer

Source: Reference 6

Funding sources and prevention of infectious diseases in Europe for STD's research:

Many U.K agencies are working to improve the health of world’s population. Under the Global Health Initiative (GHI), there is a concerted effort to improve coordination across U.S. agencies to increase efficiencies and align investments with recipient country priorities, with the aim of making programs sustainable. Some of the major funding agencies include:

1)      Centres for disease control and prevention

2)      NIH

3)      The global fund to fight AIDS, TB and Malaria.

4)      UNAIDS

5)      ASM

6)      AAAS

7)      ASTMH

8)      IDSA etc.